Patents by Inventor R. Blake Pepinsky
R. Blake Pepinsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090099078Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.Type: ApplicationFiled: January 26, 2007Publication date: April 16, 2009Inventors: Daniel H.S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
-
Publication number: 20090062199Abstract: Nogo receptor 1 (NgR1) is a leucine rich repeat protein that forms part of a signaling complex that modulates axon regeneration. Previous studies have shown that the entire LRR region of Nogo receptor-1, including the C-terminal cap of LRR, LRRCT, is needed for ligand binding, and that the adjacent CT stalk of the Nogo receptor-1 contributes to interaction with its co-receptors. The present invention is directed to the use of certain Nogo receptor-1 and Nogo receptor-2 polypeptides and polypeptide fragments for promoting neurite outgrowth, neuronal survival, and axonal regeneration in CNS neurons. The invention features molecules and methods useful for inhibiting neurite outgrowth inhibition, promoting neuronal survival, and/or promoting axonal regeneration in CNS neurons.Type: ApplicationFiled: August 25, 2006Publication date: March 5, 2009Applicant: Biogen Idec MA Inc.Inventors: Dingyi Wen, Daniel H.S. Lee, R. Blake Pepinsky
-
Publication number: 20090054632Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.Type: ApplicationFiled: August 20, 2007Publication date: February 26, 2009Applicants: Biogen Idec MA Inc., Curis, Inc.Inventors: R. Blake Pepinsky, Alphonse Galdes, Ellen A. Garber, Darren P. Baker, Jeffery A. Porter, Frederick R. Taylor, Kevin P. Williams, Russell C. Petter, Kathryn Strauch, Paul H. Weinreb, Dingyi Wen, Chenhui Zeng
-
Publication number: 20090017039Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.Type: ApplicationFiled: August 17, 2007Publication date: January 15, 2009Applicant: BIOGEN IDES MA INCInventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao
-
Patent number: 7465705Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.Type: GrantFiled: February 10, 2005Date of Patent: December 16, 2008Assignees: Yale University, Biogen Idec MA Inc.Inventors: Daniel H. S. Lee, R. Blake Pepinsky, Weiwei Li, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W. Y. Sah, Sylvia A. Rabacchi
-
Publication number: 20080306212Abstract: A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.Type: ApplicationFiled: June 27, 2008Publication date: December 11, 2008Applicant: Biogen Idec MA Inc.Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Paula Ann Boriack-Sjodin, Stephan S. Miller, Anthony Rossomando, Laura Silvian
-
Publication number: 20080274112Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.Type: ApplicationFiled: January 30, 2004Publication date: November 6, 2008Inventors: Daniel H.S. Lee, R. Blake Pepinsky, Weiwei Li, Sylvia A. Rabacchi, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W.Y. Sah
-
Patent number: 7442370Abstract: A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin.Type: GrantFiled: January 31, 2003Date of Patent: October 28, 2008Assignee: Biogen Idec MA Inc.Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Paula Ann Boriack-Sjodin, Stephan S. Miller, Anthony Rossomando, Laura Silvian
-
Publication number: 20080249287Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.Type: ApplicationFiled: August 18, 2005Publication date: October 9, 2008Applicant: Biogen Idec MA Inc.Inventors: Anthony Rossomando, R. Blake Pepinsky, Bangjian Gong
-
Publication number: 20070238650Abstract: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.Type: ApplicationFiled: April 16, 2004Publication date: October 11, 2007Inventors: Dinah Sah, R. Blake Pepinsky, Anthony Rossomando
-
Patent number: 7196112Abstract: Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.Type: GrantFiled: July 16, 2004Date of Patent: March 27, 2007Assignee: Biogen Idec MA Inc.Inventors: Wen-Cherng Lee, R. Blake Pepinsky, Mark Cornebise, Daniel Scott, Russell C. Petter
-
Patent number: 6897297Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.Type: GrantFiled: May 26, 2000Date of Patent: May 24, 2005Assignees: Curis, Inc., Biogen Idec Inc.Inventors: R. Blake Pepinsky, Chenhui Zeng, Darren P. Baker, Dingyi Wen, Kevin P. Williams, Ellen A. Garber, Kathryn L. Strauch, Frederick R. Taylor, Paul H. Weinreb, Russell C. Petter, Alphonse Galdes, Jeffrey Porter
-
Publication number: 20040038876Abstract: A hedgehog polypeptide comprising hedgehog coupled to a polymer containing a polyalkylene glycol moiety wherein the hedgehog and the polyalkylene glycol moiety are arranged such that the hedgehog has an enhanced bioavailability relative to another hedgehog lacking the polymer and exhibits no decrease in activity as compared to non-conjugated hedgehog. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.Type: ApplicationFiled: September 12, 2002Publication date: February 26, 2004Inventors: R. Blake Pepinsky, Frederick R. Taylor, Ellen A. Garber
-
Publication number: 20030166543Abstract: Variants of hedgehog protein that contain N-terminal modifications are described that can block hedgehog function; thus allowing these variants to serve as functional antagonists. These peptides have a primary amino acid sequence lacking the ability to elicit a hedgehog-dependent response in C3H 10T1/2 cells but having the ability to bind to the hedgehog receptor, patched-1. Methods for producing such functional antagonists and methods of using the functional antagonists are also described.Type: ApplicationFiled: June 5, 2002Publication date: September 4, 2003Inventors: Kevin Williams, Paul Rayhorn, Ellen A. Garber, R. Blake Pepinsky
-
Patent number: 6444793Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.Type: GrantFiled: June 3, 1999Date of Patent: September 3, 2002Assignees: Curis, Inc., Biogen, Inc.Inventors: R. Blake Pepinsky, Darren P. Baker, Dingyi Wen, Kevin P. Williams, Ellen A. Garber, Frederick R. Taylor, Alphonse Galdes, Jeffrey Porter
-
Patent number: 6316003Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which include HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: April 28, 1994Date of Patent: November 13, 2001Assignees: Whitehead Institute for Biomedical Research, Johns Hopkins Univ. School of Medicine, Biogen, Inc.Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
-
Patent number: 6127332Abstract: A IFN-.beta. mutein in which phe (F), tyr (Y), trp (W) or his (H) is substituted for val (V) at position 101, when numbered in accordance with wild type IFN-.beta., DNA sequences encoding these IFN-.beta. muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an IFN-.beta. mutein, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing IFN-.beta. muteins and methods for treating viral infections, cancer or tumors, undesired cell proliferation, or for immunomodulation.Type: GrantFiled: August 18, 1997Date of Patent: October 3, 2000Assignee: Biogen, Inc.Inventors: Susan E. Goelz, Richard L. Cate, E. Pingchang Chow, R. Blake Pepinsky
-
Patent number: 5804604Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: May 25, 1995Date of Patent: September 8, 1998Assignee: Biogen, Inc.Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
-
Patent number: 5747641Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: May 25, 1995Date of Patent: May 5, 1998Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
-
Patent number: 5674980Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.Type: GrantFiled: May 25, 1995Date of Patent: October 7, 1997Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky